{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:02:33Z","timestamp":1783443753293,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jceh.2025.102540","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:45:33Z","timestamp":1741049133000},"page":"102540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["No Differences in Risk of Cirrhosis or Hepatocellular Carcinoma Among Treatment Na\u00efve Chronic Hepatitis B Patients by Baseline Hepatitis B Viral Load: A Propensity Score Weighted Analysis"],"prefix":"10.1016","volume":"15","author":[{"given":"Zeyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice H.","family":"Jou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8923-2806","authenticated-orcid":false,"given":"Robert J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2025.102540_bib1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.102540_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2025.102540_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae571","article-title":"Sociodemographic disparities in hepatitis B treatment: a real-world analysis of 3 safety-net health systems in the United States","volume":"11","author":"Wong","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jceh.2025.102540_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jhep.2024.02.033","article-title":"Sex and ethnic disparities in hepatitis B evaluation and treatment across the world","volume":"81","author":"Kudaravalli","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102540_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000081","article-title":"Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system","volume":"7","author":"Wang","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2025.102540_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MLR.0000000000001825","article-title":"Gaps and disparities in chronic hepatitis B monitoring and treatment in the United States, 2016-2019","volume":"61","author":"Hang Pham","year":"2023","journal-title":"Med Care"},{"key":"10.1016\/j.jceh.2025.102540_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7018","article-title":"Racial disparities in treatment initiation and outcomes of chronic hepatitis B virus infection in north America","volume":"6","author":"Khalili","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jceh.2025.102540_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2021.08.019","article-title":"Substantial gaps in evaluation and treatment of patients with hepatitis B in the US","volume":"76","author":"Ye","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102540_bib9","first-page":"649","article-title":"Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B","volume":"73","author":"Choi","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2025.102540_bib10","article-title":"Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B","volume":"132","author":"Choi","year":"2022","journal-title":"JCI (J Clin Investig)"},{"key":"10.1016\/j.jceh.2025.102540_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.14740\/gr1735","article-title":"Association of baseline hepatitis B virus DNA and on-treatment risk of cirrhosis and hepatocellular carcinoma","volume":"17","author":"Yang","year":"2024","journal-title":"Gastroenterol Res"},{"key":"10.1016\/j.jceh.2025.102540_bib12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.15725","article-title":"Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients","volume":"51","author":"Kim","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2025.102540_bib13","article-title":"On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B","volume":"5","author":"Yang","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2025.102540_bib14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2025.102540_bib15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/apt.16786","article-title":"Risk of hepatocellular carcinoma in treatment-naive chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States","volume":"55","author":"W Ray Kim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2025.102540_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688325000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688325000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:14:20Z","timestamp":1751393660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688325000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0973688325000404"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2025.102540","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No Differences in Risk of Cirrhosis or Hepatocellular Carcinoma Among Treatment Na\u00efve Chronic Hepatitis B Patients by Baseline Hepatitis B Viral Load: A Propensity Score Weighted Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2025.102540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102540"}}